D
Apollomics, Inc. APLM
$18.60 $0.603.33% NASDAQ
Recommendation
Prev Close
$18.00
Volume
5,900
Avg Vol (90D)
47,008
Market Cap
$38.63M
Dividend & Yield
--
52-Week Range
$3.66 - $42.12
P/E (TTM)
--
EPS (TTM)
-$28.29
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Apollomics Inc trading resumes
12/30/2025 - The Fly
Apollomics Inc trading halted, volatility trading pause
12/30/2025 - The Fly
Apollomics H1 Loss Narrows
12/23/2025 - Nasdaq News: Markets
Apollomics (NASDAQ:APLM) Upgraded at Wall Street Zen
12/23/2025 - Zolmax
Apollomics Reports First Half 2025 Financial Results
12/22/2025 - GuruFocus
Apollomics GAAP EPS of -$11.37
12/22/2025 - SeekingAlpha.com: All News
Apollomics GAAP EPS of -$11.37
12/22/2025 - Seeking Alpha - Healthcare
Apollomics Reports First Half 2025 Financial Results
12/22/2025 - Globe Newswire
Apollomics (NASDAQ:APLM) Upgraded to Sell at Wall Street Zen
11/23/2025 - Ticker Report
Apollomics Inc trading resumes
11/21/2025 - TipRanks Financial Blog
Apollomics Inc trading resumes
11/21/2025 - The Fly
Apollomics Inc trading halted, volatility trading pause
11/21/2025 - TipRanks Financial Blog
Apollomics Inc trading halted, volatility trading pause
11/21/2025 - The Fly
Apollomics (APLM) Reaches $5M Settlement to Resolve Cayman Islands Litigation
11/19/2025 - GuruFocus
Apollomics Announces Settlement of Cayman Litigation
11/19/2025 - GuruFocus
Apollomics Announces Settlement of Cayman Litigation
11/19/2025 - GuruFocus
Apollomics announces settlement of Cayman litigation
11/19/2025 - TipRanks Financial Blog
Apollomics announces settlement of Cayman litigation
11/19/2025 - The Fly
Apollomics Announces Settlement of Cayman Litigation
11/19/2025 - Globe Newswire
Apollomics Inc trading resumes
11/18/2025 - TipRanks Financial Blog
Apollomics Inc trading resumes
11/18/2025 - The Fly
Apollomics Inc trading halted, volatility trading pause
11/18/2025 - TipRanks Financial Blog
Apollomics Inc trading halted, volatility trading pause
11/18/2025 - The Fly
Apollomics Announces Changes to its Board of Directors and Composition of Committees
11/18/2025 - GuruFocus
Apollomics Announces Changes to its Board of Directors and Composition of Committees
11/18/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$6.93M
EBITDA (TTM)
-$26.36M
EBIT (TTM)
-$26.42M
Net Income (TTM)
-$31.19M
Balance Sheet
Total Assets (Q)
$11.12M
Total Debt (Q)
$744.00K
Total Liabilities (Q)
$15.52M
Book Value Per Share (Q)
-$3.99
Cash Flow
Cash from Operations (TTM)
-$20.38M
Cash from Investing (TTM)
$284.00K
Cash from Financing (TTM)
-$3.73M
Net Change in Cash (TTM)
-$23.84M
Filings
Filing Date
Monday, December 22, 2025
Period Date
Monday, June 30, 2025
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
0.78
7-Day Total Return
-6.16%
30-Day Total Return
4.32%
60-Day Total Return
-10.83%
90-Day Total Return
52.71%
Year to Date Total Return
-3.63%
1-Year Total Return
99.46%
2-Year Total Return
-77.59%
3-Year Total Return
-98.21%
5-Year Total Return
--
52-week Low
Aug 29, 2025 - $3.66
52-week High
Oct 15, 2025 - $42.12
Valuation
Market Cap
$38.63M - Nano Cap
Enterprise Value
$37.27M
Price/Sales (TTM)
2.87
Price/Book (Q)
-4.52
Dividends and Shares
Shares Outstanding
1.10M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.apollomicsinc.com
Phone Number
650 209 4055
Address
989 East Hillsdale Blvd.
Foster City, CA 94404
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to... more
NASDAQ 01/26/2026 11:39AM Eastern Quotes delayed